Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates.

Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, St Aubin LB, Russ C; Flexible Quit Date Study Group.

Nicotine Tob Res. 2012 Mar;14(3):343-50. doi: 10.1093/ntr/ntr220. Epub 2011 Nov 11.

2.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
3.

Varenicline: a novel pharmacotherapy for smoking cessation.

Jiménez-Ruiz C, Berlin I, Hering T.

Drugs. 2009 Jul 9;69(10):1319-38. doi: 10.2165/00003495-200969100-00003. Review.

PMID:
19583451
4.

Varenicline in the management of smoking cessation: a single technology appraisal.

Hind D, Tappenden P, Peters J, Kenjegalieva K.

Health Technol Assess. 2009 Sep;13 Suppl 2:9-13. doi: 10.3310/hta13suppl2/02. Review.

5.

Varenicline in smoking cessation.

Tonstad S, Rollema H.

Expert Rev Respir Med. 2010 Jun;4(3):291-9. doi: 10.1586/ers.10.27. Review.

PMID:
20524911
6.
7.

Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.

Keating GM, Lyseng-Williamson KA.

Pharmacoeconomics. 2010;28(3):231-54. doi: 10.2165/11204380-000000000-00000. Review.

PMID:
20108995
8.

[On oral medications, especially varenicline].

Kurioka N.

Nihon Rinsho. 2013 Mar;71(3):487-92. Review. Japanese.

PMID:
23631241
9.

Varenicline: new treatment with efficacy in smoking cessation.

Reus VI, Obach RS, Coe JW, Faessel H, Rollema H, Watsky E, Reeves K.

Drugs Today (Barc). 2007 Feb;43(2):65-75. Review.

PMID:
17353944
10.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
11.

Varenicline: a review of its use as an aid to smoking cessation therapy.

Keating GM, Siddiqui MA.

CNS Drugs. 2006;20(11):945-60. Review.

PMID:
17044731
12.

Varenicline for tobacco dependence: panacea or plight?

Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, Foulds J.

Expert Opin Pharmacother. 2011 Aug;12(11):1799-812. doi: 10.1517/14656566.2011.587121. Epub 2011 Jun 6. Review.

13.

Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis.

Leung LK, Patafio FM, Rosser WW.

BMC Clin Pharmacol. 2011 Sep 28;11:15. doi: 10.1186/1472-6904-11-15. Review.

14.

Smoking cessation: an overview of treatment options with a focus on varenicline.

Stack NM.

Pharmacotherapy. 2007 Nov;27(11):1550-7. Review.

PMID:
17963463
15.

Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.

Hays JT, Ebbert JO.

Drugs. 2010 Dec 24;70(18):2357-72. doi: 10.2165/11538190-000000000-00000. Review.

PMID:
21142259
16.

Varenicline and evaluated outcomes in smoking cessation programmes.

Santus P, Bassi L, Airoldi A, Giovannelli F, Radovanovic D.

Monaldi Arch Chest Dis. 2013 Mar;79(1):20-6. Review.

17.

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Singh S, Loke YK, Spangler JG, Furberg CD.

CMAJ. 2011 Sep 6;183(12):1359-66. doi: 10.1503/cmaj.110218. Epub 2011 Jul 4. Review.

18.

Improvement of restless legs syndrome by varenicline as antismoking treatment.

Romigi A, Vitrani G.

J Clin Sleep Med. 2013 Oct 15;9(10):1089-90. doi: 10.5664/jcsm.3092. Review.

19.

Varenicline in the treatment of alcohol use disorders.

Erwin BL, Slaton RM.

Ann Pharmacother. 2014 Nov;48(11):1445-55. doi: 10.1177/1060028014545806. Epub 2014 Aug 5. Review.

PMID:
25095786
20.

An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

Perkins KA, Lerman C.

Psychopharmacology (Berl). 2014 Jan;231(1):1-11. doi: 10.1007/s00213-013-3364-6. Epub 2013 Dec 3. Review.

Items per page

Supplemental Content

Write to the Help Desk